PH26117A - Therapeutic use of the isopropyl ester derivative of monosialoganglioside in nervous pathologies with an inflammatory component - Google Patents

Therapeutic use of the isopropyl ester derivative of monosialoganglioside in nervous pathologies with an inflammatory component Download PDF

Info

Publication number: PH26117A
Authority: PH; Philippines
Prior art keywords: isopropyl ester; administered; compound; topical; administration
Prior art date: 1988-07-19

Application number

PH38954A

Other languages

English (en)

Inventor

Francesco Della Valle

Aurelio Romeo

Original Assignee

Fidia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-07-19

Filing date

1989-07-17

Publication date

1992-02-24

1989-07-17 Application filed by Fidia Spa filed Critical Fidia Spa

1992-02-24 Publication of PH26117A publication Critical patent/PH26117A/en

Links

-1 isopropyl ester Chemical class 0.000 title claims description 47
230000007170 pathology Effects 0.000 title claims description 12
230000002757 inflammatory effect Effects 0.000 title claims description 6
230000001225 therapeutic effect Effects 0.000 title description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 33
150000002270 gangliosides Chemical class 0.000 claims description 32
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 28
238000000034 method Methods 0.000 claims description 26
150000001875 compounds Chemical class 0.000 claims description 16
238000011282 treatment Methods 0.000 claims description 16
150000002148 esters Chemical class 0.000 claims description 15
230000000699 topical effect Effects 0.000 claims description 15
229960000905 indomethacin Drugs 0.000 claims description 14
230000000694 effects Effects 0.000 claims description 13
230000005764 inhibitory process Effects 0.000 claims description 12
230000003110 anti-inflammatory effect Effects 0.000 claims description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
230000002322 anti-exudative effect Effects 0.000 claims description 10
239000011780 sodium chloride Substances 0.000 claims description 10
206010030113 Oedema Diseases 0.000 claims description 8
239000000679 carrageenan Substances 0.000 claims description 8
235000010418 carrageenan Nutrition 0.000 claims description 8
229920001525 carrageenan Polymers 0.000 claims description 8
229940113118 carrageenan Drugs 0.000 claims description 8
238000007920 subcutaneous administration Methods 0.000 claims description 8
238000011200 topical administration Methods 0.000 claims description 8
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 8
241001465754 Metazoa Species 0.000 claims description 7
238000007912 intraperitoneal administration Methods 0.000 claims description 7
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
239000000902 placebo Substances 0.000 claims description 5
229940068196 placebo Drugs 0.000 claims description 5
230000009885 systemic effect Effects 0.000 claims description 5
230000003501 anti-edematous effect Effects 0.000 claims description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 4
208000003435 Optic Neuritis Diseases 0.000 claims description 3
229960001340 histamine Drugs 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
206010023332 keratitis Diseases 0.000 claims description 3
206010034674 peritonitis Diseases 0.000 claims description 3
208000008035 Back Pain Diseases 0.000 claims description 2
101800004538 Bradykinin Proteins 0.000 claims description 2
206010008334 Cervicobrachial syndrome Diseases 0.000 claims description 2
208000002691 Choroiditis Diseases 0.000 claims description 2
206010010741 Conjunctivitis Diseases 0.000 claims description 2
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 2
206010022557 Intermediate uveitis Diseases 0.000 claims description 2
206010022941 Iridocyclitis Diseases 0.000 claims description 2
102100035792 Kininogen-1 Human genes 0.000 claims description 2
208000008930 Low Back Pain Diseases 0.000 claims description 2
208000003971 Posterior uveitis Diseases 0.000 claims description 2
201000001949 Retinal Vasculitis Diseases 0.000 claims description 2
206010038910 Retinitis Diseases 0.000 claims description 2
201000011101 acute retrobulbar neuritis Diseases 0.000 claims description 2
201000004612 anterior uveitis Diseases 0.000 claims description 2
208000010217 blepharitis Diseases 0.000 claims description 2
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
229960000991 ketoprofen Drugs 0.000 claims description 2
210000000653 nervous system Anatomy 0.000 claims description 2
208000022670 retrobulbar neuritis Diseases 0.000 claims description 2
229940076279 serotonin Drugs 0.000 claims description 2
206010015084 Episcleritis Diseases 0.000 claims 1
208000007514 Herpes zoster Diseases 0.000 claims 1
206010039705 Scleritis Diseases 0.000 claims 1
206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 1
238000012986 modification Methods 0.000 claims 1
230000004048 modification Effects 0.000 claims 1
230000002980 postoperative effect Effects 0.000 claims 1
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 18
239000000499 gel Substances 0.000 description 15
241000700159 Rattus Species 0.000 description 11
239000000203 mixture Substances 0.000 description 11
239000000047 product Substances 0.000 description 11
239000000243 solution Substances 0.000 description 11
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
210000002683 foot Anatomy 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 7
229940106189 ceramide Drugs 0.000 description 7
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 7
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 7
239000000825 pharmaceutical preparation Substances 0.000 description 7
239000003826 tablet Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
239000013543 active substance Substances 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
230000003502 anti-nociceptive effect Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
210000000416 exudates and transudate Anatomy 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000008363 phosphate buffer Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
235000019759 Maize starch Nutrition 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
239000006071 cream Substances 0.000 description 3
230000032050 esterification Effects 0.000 description 3
238000005886 esterification reaction Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
229930182830 galactose Natural products 0.000 description 3
229960003082 galactose Drugs 0.000 description 3
239000008103 glucose Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
239000008101 lactose Substances 0.000 description 3
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
210000001428 peripheral nervous system Anatomy 0.000 description 3
FLKPEMZONWLCSK-UHFFFAOYSA-N phthalic acid di-n-ethyl ester Natural products CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 3
NBMVYETVBIIWFF-AACOHXQBSA-N propan-2-yl (2s,4s,5r,6r)-5-acetamido-2-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[( Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(=O)OC(C)C)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 NBMVYETVBIIWFF-AACOHXQBSA-N 0.000 description 3
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
238000011084 recovery Methods 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
229920001800 Shellac Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
VHIORVCHBUEWEP-ZSCHJXSPSA-N [(5s)-5-amino-5-carboxypentyl]azanium;2-(3-benzoylphenyl)propanoate Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 VHIORVCHBUEWEP-ZSCHJXSPSA-N 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
230000001524 infective effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
210000000944 nerve tissue Anatomy 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000035699 permeability Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
229960003415 propylparaben Drugs 0.000 description 2
239000004208 shellac Substances 0.000 description 2
229940113147 shellac Drugs 0.000 description 2
235000013874 shellac Nutrition 0.000 description 2
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
102100022096 Acid-sensing ion channel 5 Human genes 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
101000901085 Homo sapiens Acid-sensing ion channel 5 Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
101150046735 LEPR gene Proteins 0.000 description 1
101150063827 LEPROT gene Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000252067 Megalops atlanticus Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
101100043067 Mus musculus Sox8 gene Proteins 0.000 description 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
208000008765 Sciatica Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
210000005252 bulbus oculi Anatomy 0.000 description 1
150000001720 carbohydrates Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
125000001549 ceramide group Chemical group 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229930182478 glucoside Natural products 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
UOJMTSCORVQOHS-UHFFFAOYSA-N pachypodol Natural products COc1cc(ccc1O)C2=C(C)C(=O)c3c(O)cc(C)cc3O2 UOJMTSCORVQOHS-UHFFFAOYSA-N 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
LMHHRCOWPQNFTF-UHFFFAOYSA-N s-propan-2-yl azepane-1-carbothioate Chemical compound CC(C)SC(=O)N1CCCCCC1 LMHHRCOWPQNFTF-UHFFFAOYSA-N 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
229940084106 spermaceti Drugs 0.000 description 1
239000012177 spermaceti Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000008733 trauma Effects 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Biotechnology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PH38954A 1988-07-19 1989-07-17 Therapeutic use of the isopropyl ester derivative of monosialoganglioside in nervous pathologies with an inflammatory component PH26117A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT8848208A IT1224513B (it)	1988-07-19	1988-07-19	Uso terapeutico del derivato estere isopropilico del monosialogangliosi de in patologie ad interessamento nervoso con componente infiammatoria

Publications (1)

Publication Number	Publication Date
PH26117A true PH26117A (en)	1992-02-24

Family

ID=11265246

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH38954A PH26117A (en)	1988-07-19	1989-07-17	Therapeutic use of the isopropyl ester derivative of monosialoganglioside in nervous pathologies with an inflammatory component

Country Status (10)

Country	Link
EP (1)	EP0351784B1 (de)
JP (1)	JPH0278622A (de)
AT (1)	ATE97812T1 (de)
AU (1)	AU624164B2 (de)
DE (1)	DE68911049T2 (de)
DK (1)	DK354589A (de)
ES (1)	ES2061821T3 (de)
IT (1)	IT1224513B (de)
PH (1)	PH26117A (de)
ZA (1)	ZA895367B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09278653A (ja) *	1996-04-05	1997-10-28	Santen Pharmaceut Co Ltd	網膜疾患治療剤
US6998392B2 (en) *	2003-04-02	2006-02-14	Mti Meta Tech Inc.	Formulation to treat or prevent parasitic infection
US8536140B2 (en)	2004-03-12	2013-09-17	Mti Meta Tech Inc.	Methods for treating inflammatory bowel disease
US7851451B2 (en)	2004-03-12	2010-12-14	Mti Meta Tech Inc.	Formulations for mediating inflammatory bowel disorders
CN104490837A (zh) *	2014-12-30	2015-04-08	哈尔滨医科大学科技开发总公司	单唾液酸四己糖神经节苷脂钠的口服制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1199116B (it) *	1984-07-03	1988-12-30	Fidia Farmaceutici	Derivati di gangliosidi

1988
- 1988-07-19 IT IT8848208A patent/IT1224513B/it active
1989
- 1989-07-14 ZA ZA895367A patent/ZA895367B/xx unknown
- 1989-07-17 PH PH38954A patent/PH26117A/en unknown
- 1989-07-18 AU AU38190/89A patent/AU624164B2/en not_active Ceased
- 1989-07-18 EP EP89113160A patent/EP0351784B1/de not_active Expired - Lifetime
- 1989-07-18 AT AT89113160T patent/ATE97812T1/de not_active IP Right Cessation
- 1989-07-18 DE DE68911049T patent/DE68911049T2/de not_active Expired - Fee Related
- 1989-07-18 ES ES89113160T patent/ES2061821T3/es not_active Expired - Lifetime
- 1989-07-18 DK DK354589A patent/DK354589A/da not_active Application Discontinuation
- 1989-07-19 JP JP1187237A patent/JPH0278622A/ja active Pending

Also Published As

Publication number	Publication date
DE68911049D1 (de)	1994-01-13
EP0351784A3 (en)	1990-12-27
JPH0278622A (ja)	1990-03-19
IT1224513B (it)	1990-10-04
DE68911049T2 (de)	1994-06-01
EP0351784B1 (de)	1993-12-01
EP0351784A2 (de)	1990-01-24
DK354589D0 (da)	1989-07-18
ATE97812T1 (de)	1993-12-15
AU3819089A (en)	1990-01-25
AU624164B2 (en)	1992-06-04
DK354589A (da)	1990-01-20
ES2061821T3 (es)	1994-12-16
ZA895367B (en)	1990-04-25
IT8848208A0 (it)	1988-07-19

Publication	Publication Date	Title
US5045532A (en)	1991-09-03	Inner esters of gangliosides with analgesic-antiinflammatory activity
AU721709B2 (en)	2000-07-13	Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions
JPH0524135B2 (de)	1993-04-06
CN106344595B (zh)	2020-06-19	褐藻胶寡糖及其衍生物在制备治疗疼痛药物中的应用
JPH01308292A (ja)	1989-12-12	ガングリオシド誘導体の製造法
JPH05502864A (ja)	1993-05-20	薬剤
US20140018316A1 (en)	2014-01-16	Ophthalmic pharmaceutical composition
US4639437A (en)	1987-01-27	Kit or device and method for administering gangliosides and derivatives thereof by inhalation and pharmaceutical compositions suitable therefor
DE68904507T2 (de)	1993-06-09	Verwendung von inositoltriphosphat bei der behandlung der beschaedigung von gewebe.
JPH0149276B2 (de)	1989-10-24
US20070167517A1 (en)	2007-07-19	Stabilized derivatives of ascorbic aicd
US5183807A (en)	1993-02-02	Use of monosialoganglioside gm, to prevent the development of tolerance to the analgesic effect of morphine and related drugs
PH26117A (en)	1992-02-24	Therapeutic use of the isopropyl ester derivative of monosialoganglioside in nervous pathologies with an inflammatory component
US4784992A (en)	1988-11-15	Phosphorylalkanolamide derivatives of L-carnitine and pharmaceutical compositions containing same
KR970005346B1 (ko)	1997-04-15	사카라이드 유도체
CA1038402A (en)	1978-09-12	Therapeutic agents
DE69033027T2 (de)	1999-11-25	Di-lysogangliosidderivate
US6475520B1 (en)	2002-11-05	Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation
JPS6317840B2 (de)	1988-04-15
US3973031A (en)	1976-08-03	Gulonic acid salt
WO1995014476A1 (en)	1995-06-01	The use of an ester of inositoltrisphosphate for the preparing of an analgetic medicament
KR800001509B1 (ko)	1980-12-19	결정형 에스친의 제조방법
WO2022004873A1 (ja)	2022-01-06	クルクミンモノグルクロニドの塩
KR20210040941A (ko)	2021-04-14	통증 치료에서의 만누론 이산 조성물의 용도
CN102462726A (zh)	2012-05-23	白树总生物碱及多羟基生物碱化合物的提取、分离及用途